Skip to main content
SpringerLink
Log in

Hodgkin’s Lymphoma

  • Chapter
  • First Online:
Fertility Preservation in Oncological and Non-Oncological Diseases

  • 330 Accesses

Abstract

Hodgkin’s lymphoma occurs frequently in younger age. Fertility preservation is an important issue as survival rates are very high and some of the treatments are highly gonadotoxic.

Two relevant chemotherapy protocols are performed in Hodgkin’s lymphoma: ABVD and escalated BEACOPP. Some patients also receive local radiotherapy. Risk of amenorrhoea is >20% in women ≥30 years receiving any escalated BEACOPP therapy, and in women <30 years receiving ≥6 cycles escalated BEACOPP. Oligospermia can be detected among male patients independent of chemotherapy regimens and radiation. Azoospermia depends on intensity of the chemotherapy regimen. Therefore, women and men who are treated with these regimens should be advised to undergo fertility preservation therapy. The treatments which can be offered are freezing of oocytes, freezing of ovarian tissue and GnRHa, alone or in combination, as well as freezing of sperm or testicular tissue.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116(19):3724–34. https://doi.org/10.1182/blood-2010-05-282632.

    Article  PubMed  CAS  Google Scholar 

  2. Robert-Koch-Institut (2016). 3.28 Morbus Hodgkin. Krebs Deutschl. 122–5.

    Google Scholar 

  3. von Wolff M, Bruckner T, Strowitzki TGA. Fertility preservation: ovarian response to freeze oocytes is not affected by different malignant diseases-an analysis of 992 stimulations. J Assist Reprod Genet. 2018;35(9):1713–9.

    Article  Google Scholar 

  4. Glimelius I, Ekberg S, Jerkeman M, Chang ET, Björkholm M, Andersson TML, et al. Long-term survival in young and middle-aged Hodgkin lymphoma patients in Sweden 1992-2009-trends in cure proportions by clinical characteristics. Am J Hematol. 2015;90(12):1128–34. https://doi.org/10.1002/ajh.24184.

    Article  PubMed  CAS  Google Scholar 

  5. Pulte D, Jansen L, Gondos A, Emrich K, Holleczek B, Katalinic A, et al. Improved population level survival in younger Hodgkin lymphoma patients in Germany in the early twenty-first century. Br J Haematol. 2014;164(6):851–7. https://doi.org/10.1111/bjh.12722.

    Article  PubMed  Google Scholar 

  6. Skoetz N, Trelle S, Rancea M, Haverkamp H, Diehl V, Engert A, et al. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin’s lymphoma: a systematic review and network meta-analysis. Lancet Oncol. 2013;14(10):943–52. https://doi.org/10.1016/S1470-2045(13)70341-3.

    Article  PubMed  Google Scholar 

  7. Behringer K, Goergen H, Hitz F, Zijlstra JM, Greil R, Markova J, et al. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin’s lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet. 2014;385(9976):1418–27. https://doi.org/10.1016/S0140-6736(14)61469-0.

    Article  PubMed  CAS  Google Scholar 

  8. Von Tresckow B, Plütschow A, Fuchs M, Klimm B, Markova J, Lohri A, et al. Dose-intensification in early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin study group HD14 trial. J Clin Oncol. 2012;30(9):907–13. https://doi.org/10.1200/JCO.2011.38.5807.

    Article  CAS  Google Scholar 

  9. Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379(9828):1791–9. https://doi.org/10.1016/S0140-6736(11)61940-5.

    Article  PubMed  CAS  Google Scholar 

  10. S3-Leitlinie Diagnostik, Therapie und Nachsorge des Hodgkin Lymphoms bei erwachsenen. Patienten. 2019: 1–183.

    Google Scholar 

  11. van Beek RD, Smit M, van den Heuvel-Eibrink MM, de Jong FH, Hakvoort-Cammel FG, van den Bos C, et al. Inhibin B is superior to FSH as a serum marker for spermatogenesis in men treated for Hodgkin’s lymphoma with chemotherapy during childhood. Hum Reprod. 2007;22(12):3215–22. https://doi.org/10.1093/humrep/dem313.

    Article  PubMed  CAS  Google Scholar 

  12. Kiserud CE, Fosså A, Bjøro T, Holte H, Cvancarova M, Fosså SD. Gonadal function in male patients after treatment for malignant lymphomas, with emphasis on chemotherapy. Br J Cancer. 2009;10:455–63. https://doi.org/10.1038/sj.bjc.6604892.

    Article  CAS  Google Scholar 

  13. Kulkarni S, et al. Gonadal function following ABVD therapy for Hodgkin‘ s disease. Am J Clin Oncol. 1997;20(4):354–7.

    Article  CAS  Google Scholar 

  14. Behringer K, Breuer K, Reineke T, May M, Nogova L, Klimm B. Secondary amenorrhea after Hodgkin’s lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin’s lymphoma study group. J Clin Oncol. 2005;23(30):7555–64. https://doi.org/10.1200/JCO.2005.08.138.

    Article  PubMed  Google Scholar 

  15. Behringer K, Mueller H, Goergen H, Thielen I, Eibl AD, Stumpf V, et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin study group HD13 to HD15 trials. J Clin Oncol. 2013;31(2):231–9. https://doi.org/10.1200/JCO.2012.44.3721.

    Article  PubMed  CAS  Google Scholar 

  16. Weibull CE, Eloranta S, Smedby KE, Bjorkholm M, Kristinsson SY, Johansson AL, et al. Pregnancy and the risk of relapse in patients diagnosed with Hodgkin lymphoma. J Clin Oncol. 2016;34(4):337–44. https://doi.org/10.1200/JCO.2015.63.3446.

    Article  PubMed  Google Scholar 

  17. Caponecchia L, Cimino G, Sacchetto R, Fiori C, Sebastianelli A, Salacone P, et al. Do malignant diseases affect semen quality? Sperm parameters of men with cancers. Andrologia. 2016;48(3):333–40.

    Article  CAS  Google Scholar 

  18. Paoli D, Rizzo F, Fiore G, Pallotti F, Pulsoni A, Annechini G, et al. Spermatogenesis in Hodgkin’s lymphoma patients: a retrospective study of semen quality before and after different chemotherapy regimens. Hum Reprod. 2016;31(2):263–72. https://doi.org/10.1093/humrep/dev310.

    Article  PubMed  CAS  Google Scholar 

  19. Seshadri T, Gook D, Lade S, Spencer A, Grigg A, Tiedemann K, et al. Lack of evidence of disease contamination in ovarian tissue harvested for cryopreservation from patients with Hodgkin lymphoma and analysis of factors predictive of oocyte yield. Br J Cancer. 2006;94(7):1007–10. https://doi.org/10.1038/sj.bjc.6603050.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  20. Meirow D, Hardan I, Dor J, Fridman E, Elizur S, Ra’anani H, et al. Searching for evidence of disease and malignant cell contamination in ovarian tissue stored from hematologic cancer patients. Hum Reprod. 2008;23(5):1007–13. https://doi.org/10.1093/humrep/den055.

    Article  PubMed  Google Scholar 

  21. Bittinger SE, Nazaretian SP, Gook DA, Parmar C, Harrup RA, Stern CJ. Detection of Hodgkin lymphoma within ovarian tissue. Fertil Steril. 2011;95(2):803e3–6. https://doi.org/10.1016/j.fertnstert.2010.07.1068.

    Article  Google Scholar 

  22. Hoekman EJ, Smit VTHBM, Fleming TP, Louwe LA, Fleuren GJ, CGJM H. Searching for metastases in ovarian tissue before autotransplantation: a tailor-made approach. Fertil Steril. 2015;103(2):469–77. https://doi.org/10.1016/j.fertnstert.2014.11.001.

    Article  PubMed  Google Scholar 

  23. Lekovich J, Lobel ALS, Stewart JD, Pereira N, Kligman I, Rosenwaks Z. Female patients with lymphoma demonstrate diminished ovarian reserve even before initiation of chemotherapy when compared with healthy controls and patients with other malignancies. J Assist Reprod Genet. 2016;33(5):657–62. https://doi.org/10.1007/s10815-016-0689-1.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Lawrenz B, Fehm T, Von Wolff M, Soekler M, Huebner S, Henes J, et al. Reduced pretreatment ovarian reserve in premenopausal female patients with Hodgkin lymphoma or non-Hodgkin-lymphoma—evaluation by using antimüllerian hormone and retrieved oocytes. Fertil Steril. 2012;98(1):141–4. https://doi.org/10.1016/j.fertnstert.2012.04.021.

    Article  PubMed  CAS  Google Scholar 

  25. Liebenthron J, Reinsberg J, van der Ven K, Saenger N, Kruessel JS, von Wolff M. Serum anti-Mullerian hormone concentration and follicle density throughout reproductive life and in different diseases—implications in fertility preservation. Hum Reprod. 2019;34(12):2513–22. https://doi.org/10.1093/humrep/dez215.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Internal Medicine Department III, Hematology and Oncology, University Hospital of Munich, Großhadern, Munich, Germany

    Carolin Bürkle

  2. Division of Gynaecological Endocrinology and Reproductive Medicine, University Women’s Hospital, University of Bern, Bern, Switzerland

    Michael von Wolff

  3. Internal Medicine Department I, Hematology and Oncology, University Hospital of Cologne, Cologne, Germany

    Karolin Behringer

Authors
  1. Carolin Bürkle
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael von Wolff
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Karolin Behringer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carolin Bürkle .

Editor information

Editors and Affiliations

  1. Division of Gynaecological Endocrinology and Reproductive Medicine, University Women’s Hospital of Bern, Bern, Switzerland

    Michael von Wolff

  2. Specialist Centre for Reproductive Medicine, Prenatal Medicine, Endocrinology and Osteology, amedes MVZ Hamburg, Hamburg, Germany

    Frank Nawroth

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Bürkle, C., von Wolff, M., Behringer, K. (2020). Hodgkin’s Lymphoma. In: von Wolff, M., Nawroth, F. (eds) Fertility Preservation in Oncological and Non-Oncological Diseases. Springer, Cham. https://doi.org/10.1007/978-3-030-47568-0_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-47568-0_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-47567-3

  • Online ISBN: 978-3-030-47568-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation